JP2000515368A5 - - Google Patents

Download PDF

Info

Publication number
JP2000515368A5
JP2000515368A5 JP1998505190A JP50519098A JP2000515368A5 JP 2000515368 A5 JP2000515368 A5 JP 2000515368A5 JP 1998505190 A JP1998505190 A JP 1998505190A JP 50519098 A JP50519098 A JP 50519098A JP 2000515368 A5 JP2000515368 A5 JP 2000515368A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998505190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/009690 external-priority patent/WO1998001564A1/en
Publication of JP2000515368A publication Critical patent/JP2000515368A/ja
Publication of JP2000515368A5 publication Critical patent/JP2000515368A5/ja
Ceased legal-status Critical Current

Links

JP10505190A 1996-07-08 1997-07-03 Hivエンベロープポリペプチドおよびワクチン Ceased JP2000515368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
US08/676,737 1996-07-08
PCT/US1997/009690 WO1998001564A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Publications (2)

Publication Number Publication Date
JP2000515368A JP2000515368A (ja) 2000-11-21
JP2000515368A5 true JP2000515368A5 (enExample) 2005-03-10

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10505190A Ceased JP2000515368A (ja) 1996-07-08 1997-07-03 Hivエンベロープポリペプチドおよびワクチン

Country Status (13)

Country Link
US (1) US6090392A (enExample)
EP (1) EP0942988A1 (enExample)
JP (1) JP2000515368A (enExample)
AP (1) AP1282A (enExample)
AU (1) AU727107B2 (enExample)
CA (1) CA2259965A1 (enExample)
ID (1) ID17767A (enExample)
IL (2) IL127701A0 (enExample)
NZ (1) NZ333500A (enExample)
OA (1) OA10954A (enExample)
TW (1) TWI221846B (enExample)
WO (1) WO1998001564A1 (enExample)
ZA (1) ZA975889B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562347B1 (en) 1998-03-12 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services Chemokine-tumor antigen fusion proteins as cancer vaccines
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
WO2002022686A2 (en) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
WO2002022687A2 (en) 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
US20060116325A1 (en) * 2001-02-15 2006-06-01 Oleg Chertov Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US20050025779A1 (en) * 2003-06-12 2005-02-03 Vaxgen, Inc. HIV-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
PL1692516T3 (pl) * 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
DK1805510T3 (da) * 2004-09-08 2012-04-30 Immunaid Pty Ltd Terapeutisk strategi til behandling af autoimmune og degenerative sygdomme
ES2610781T3 (es) * 2004-09-14 2017-05-03 Argos Therapeutics, Inc. Amplificación de patógenos independiente de la cepa y vacunas para estos
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US9951106B2 (en) 2012-12-04 2018-04-24 University Of Maryland, Baltimore Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187041B1 (en) * 1984-12-24 1996-05-15 Genentech, Inc. Fusions of AIDS-related polypeptides
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
CA2078545A1 (en) * 1990-04-03 1991-10-04 Timothy J. Gregory Hiv envelope polypeptides
EP0527760B1 (en) * 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
AU700371B2 (en) * 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001500031A5 (enExample)
JP2000501771A5 (enExample)
JP2002511982A5 (enExample)
JP2000501599A5 (enExample)
JP2001507965A5 (enExample)
JP2002510439A5 (enExample)
JP2000515576A5 (enExample)
JP2002514905A5 (enExample)
JP2001503031A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2001506386A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2001506363A5 (enExample)
JP2000515368A5 (enExample)
JP2002513392A5 (enExample)
JP2000501744A5 (enExample)
JP2000502316A5 (enExample)